Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | BCL9 | O00512 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21570247 | 1.00 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MGLLHTR2AGAA | |
| SCHEMBL8818613 | 1.00 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MGLLHTR2AGAA | |
| SCHEMBL31201617 | 0.88 | HTR2A (0.49) | ALDH1A1SMN1; SMN2MGLLHTR2AGAA | |
| SCHEMBL6443753 | 0.87 | MGLL (0.54) | ALDH1A1SMN1; SMN2MGLLHTR2AGAA | |
| SCHEMBL30373891 | 0.86 | HTR2A (0.48) | ALDH1A1SMN1; SMN2MGLLHTR2AGAA | |
| SCHEMBL1872356 | 0.86 | MGLL (0.53) | ALDH1A1SMN1; SMN2MGLLHTR2AGAA | |
| SCHEMBL30374151 | 0.86 | HTR2A (0.48) | ALDH1A1SMN1; SMN2MGLLHTR2AGAA | |
| SCHEMBL7311509 | 0.85 | MAPT (0.57) | ALDH1A1SMN1; SMN2HTR2AGAAMAPT | |
| SCHEMBL7335038 | 0.85 | MAPT (0.57) | ALDH1A1SMN1; SMN2HTR2AGAAMAPT | |
| SCHEMBL8846903 | 0.83 | HCAR2 (0.53) | ALDH1A1MGLLGAAMAPTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-02-27 | — | — | US | disclosed |
| WO-2024233642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2024076873-A1 | HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE | TEON THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-116640117-A | Triazole LPAR1 antagonists and uses thereof | 武汉人福创新药物研发中心有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023109878-A1 | TRIAZASPIRO LPAR1 ANTAGONIST AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-8106232-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8101794-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101791-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101791-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101791-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090247627-A1 | AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-10-01 | — | — | US | disclosed |
| WO-2009076399-A2 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 902/4885SMN1; SMN2 1610/4885MGLL 4233/4885 |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 601/4885SMN1; SMN2 2791/4885MGLL 4391/4885 |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | ALDH1A1 911/4885SMN1; SMN2 4141/4885MGLL 275/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | ALDH1A1 3250/4885SMN1; SMN2 354/4885MGLL 1014/4885 |
| US-20090247627-A1 | AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRD1 | ALDH1A1 1590/4885SMN1; SMN2 2035/4885MGLL 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.